Related Experiment Videos
[Thrombogenesis in patients with ischemic stroke]
J Iłzecka1, Z Stelmasiak, B Dobosz
1Katedra i Klinika Neurologii Akademii Medycznej w Lublinie. jeannei@kki.net.pl
Neurologia I Neurochirurgia Polska
|March 5, 2002
Summary
Thrombin-antithrombin III complexes (TAT) were significantly elevated in ischemic stroke patients compared to controls. Higher TAT levels correlated with stroke severity and extent, indicating increased thrombin generation in these patients.
Area of Science:
- Biochemistry
- Neurology
- Hematology
Background:
- Thrombinogenesis is a key process in blood coagulation.
- Thrombin-antithrombin III complexes (TAT) are markers of thrombin activity.
- Ischemic stroke involves complex pathophysiological mechanisms, including coagulation.
Purpose of the Study:
- To evaluate thrombin-antithrombin III (TAT) complex levels in patients with ischemic stroke.
- To correlate TAT levels with stroke severity, extent, and presence of atrial fibrillation.
Main Methods:
- Blood samples were collected from 25 ischemic stroke patients and 15 controls.
- TAT complexes were quantified using enzyme-linked immunosorbent assay (ELISA) on days 1, 5, and 12 post-stroke.
- Patients were categorized by stroke extent, severity, and presence of atrial fibrillation.
Main Results:
- TAT complexes were significantly higher in ischemic stroke patients versus controls.
- Elevated TAT levels were observed in patients with larger stroke extent and more severe strokes.
- Higher TAT levels were noted in stroke patients with atrial fibrillation on day 1 compared to those without.
Conclusions:
- Ischemic stroke is associated with intense thrombinogenesis.
- TAT complex levels can serve as a biomarker for stroke severity and activity.
- Coagulation activation is a significant component of ischemic stroke pathophysiology.